Abstract
Background: Fifteen COVID-19 vaccines have been granted emergency approval before the completion of conventional phases of clinical trials. The present study aimed to analyze the neurological adverse events (AEs) post-COVID-19 vaccination and focuses on determining the association of AEs with the vaccine.
Methodology: The neurological AEs reported for COVID-19 vaccines in the WHO pharmacovigilance database (VigiBase) were extracted from the System Organ Classes - neurological disorders and investigations. Descriptive statistics are reported as percentage and frequency and the disproportionality analysis was also conducted.
Results: For the neurological system, 19,529 AEs were reported. Of these, 15,638 events were reported from BNT162b2 vaccine, 2,751 from AZD1222 vaccine, 1,075 from mRNA-1273 vaccine, eight from Vero vaccine, two from Covaxin, and for 55 AEs, vaccine name was not mentioned. The reason for more AEs reported with BNT162b2 can be maximum vaccination with BNT162b2 vaccine in the study period. According to the disproportionality analysis based on IC025 value, ageusia, anosmia, burning sensation, dizziness, facial paralysis, headache, hypoaesthesia, lethargy, migraine, neuralgia, paresis, parosmia, poor sleep quality, seizure, transient ischemic attack, and tremor are some of the AEs that can be associated with the administration of the vaccine.
Conclusion: The vaccines should be monitored for these AEs till the causality of these AEs with COVID-19 vaccines is established through further long-term follow-up studies. These neurological AEs reported in VigiBase should not be taken as conclusive and mass vaccination should be carried out to control the pandemic until a definite link of these adverse effects is established.
Keywords: sars-cov-2 (severe acute respiratory syndrome coronavirus -2), adverse events following immunization, azd1222, bnt162b2, mrna-1273, neurological disorders, covid-19 vaccines, adverse events
Introduction
COVID-19 is an acute respiratory illness caused by the SARS-CoV-2 virus. Since its initial report in December 2019 in Wuhan, China, COVID-19 has rattled the global research to combat this deadly virus. As of now on April 7, 2021, it has infected 270,791,973 individuals including 5,318,216 deaths [1]. The sudden spike in the number of cases led to a shortage of various medicines and personal protective equipment in many countries and imposed a lockdown to stop the spread of the virus further worsening the daily life of people across the globe [2-4]. The research related to the COVID-19 virus is exploring mainly four arenas- dissecting the virus itself, exploring the diagnostic tools, finding the prevention and the treatment modalities. Various modalities, repurposed drugs, complementary and alternative medicines, vitamins, nutraceuticals, and immune-boosters were being used to tackle the condition as there was no definitive treatment [5-9]. The drugs being explored for treatment include drugs like hydroxychloroquine, remdesivir, favipiravir, tocilizumab, ivermectin, baricitinib, etc. Numerous studies were conducted to observe the safety and efficacy of these drugs in COVID-19 [6,7,10-12]. As of May 19, 2021, 15 vaccines were approved for COVID-19 namely Comirnaty (BNT162b2), Moderna COVID‑19 vaccine (mRNA-1273), AstraZeneca COVID-19 vaccine (AZD1222); also known as Vaxzevria and Covishield, Sputnik V, Sputnik Light, COVID-19 vaccine Janssen (JNJ-78436735; Ad26.COV2.S), CoronaVac, BBIBP-CorV, EpiVacCorona, Convidicea (Ad5-nCoV), Covaxin, WIBP-CorV, CoviVac, ZF2001, and QazVac (QazCovid-in) [13]. In view of the initial pandemic scenario, all vaccines were granted emergency approval trials based on the data generated from the initial phases of clinical trials, before completion of all the phases of a clinical trial [14-16]. The remaining phases of clinical trials were continuing to confirm their safety and efficacy. Thus, it was imperative to monitor the adverse events reported post-COVID-19 vaccination. There were scattered reports of neurological adverse events following the COVID-19 vaccination [17-19]. Thus, the present study was planned by the authors in order to evaluate the neurological adverse events reported in the WHO pharmacovigilance database, VigiBase.
VigiBase is the global post-marketing pharmacovigilance database maintained by WHO, which contains the adverse events of approved drugs reported from all over the world [20]. VigiBase database had been used previously to analyze the safety profile of many drugs and vaccines including the therapies used for treatment and prevention of COVID-19 [6,7,10,11,21,22]. We evaluated all the neurological adverse events reported for COVID-19 vaccines in VigiBase. We also analyzed if there exists any relationship between the reported adverse events and the vaccines. This study was also planned to generate a safety signal for COVID-19 vaccines in the prime stage and provide a platform for other studies for generating or detecting the safety data of COVID-19 vaccines.
Materials and methods
The authors used VigiBase for analysis of adverse events related to COVID-19 Vaccines reported between December 15, 2020, and January 24, 2021. VigiBase is a global pharmacovigilance database established in 1978 and consists of over 20 million reports of suspected adverse events reported since its origin by its 130 member countries which represent 90% of the world population [20,23,24].
VigiBase is linked with MedDRA, WHO-ART, WHO-ICD in order to facilitate uniform data entry, retrieval, and analysis. The adverse events are reported as Individual Case Safety Report (ICSR). ICSR is also termed as “spontaneous” or “voluntary” when the reports are generated in the post-marketing phase of the drug when it is available for general use [20,23-25].
The adverse events reported in VigiBase are in a structured form that consists of information regarding three domains: patient (age, gender, country, and continent of residence), drug (name, start and end date, dose, route of administration, and the indication for use), and adverse event (type of event, onset date, seriousness, causality, and the outcome). The drugs are coded in VigiBase in alliance with the WHO Drug Dictionary enhanced including the Anatomical Therapeutic Classification. The adverse events are also reported and coded in accordance with the Medical Dictionary for Regulatory Authorities (MedDRA) and the WHO adverse reaction Terminology [25,26]. The information in the MedDRA is contained as highly standardized medical terminology to allow the global sharing of consistent regulatory information for drugs used by humans [27,28]. In the VigiBase, the information related to adverse events is recorded in accordance with MedDRA in a highly specific hierarchical order containing five levels: lowest level terms (LTTs), preferred terms (PTs), high-level terms (HLTs), high-level group terms (HLGTs), and system organ classes (SOCs) [28,29].
In the present study, the SOC and PT were used for analysis. The PT contains the specific disease, symptom, therapeutic indication, and surgical or medical procedures. The PT is arranged into SOC according to the etiology (infections and infestations), manifestation site (e.g., neurological disorder, musculoskeletal disorder), or purpose (medical or surgical procedure) [30].
The present study incorporated all suspected neurological adverse events reported in VigiBase after administration of COVID-19 vaccines - BNT162b2, AZD1222, mRNA-1273, Covaxin, and unknown vaccines (vaccine for which no name is mentioned in the ICSR form) between December 15, 2020, and January 24, 2021. The authors extracted SOC - neurological disorders and investigations from the database. The SOC investigation was cleaned further to remove all adverse events except for those related to the neurological system. The individual neurological adverse events are reported as frequency and percentage. The authors also used disproportionality analysis, the method of signal detection for the adverse events that are spontaneously reported in the database. In disproportionality analysis, the Frequentist and the Bayesian information component (IC) methods are applied to compare the drug adverse event pair with the other drug adverse events pairs of the database to evaluate if the observed frequency of the events for a drug is more than expected [31-35].
The IC was used by the authors to evaluate the relationship between the specific adverse events to COVID-19 vaccine administration. IC is a Bayesian method of signal generation, and it can avoid false-positive results when events are low [31,35]. In order to link a particular adverse event to a specific drug (COVID-19 vaccine in the current study), the lower limit of IC025 should have a positive value. Since in the present study, the frequency of many adverse events was less than four, thus the authors used only IC025 values and not the ROR or PRR values. Although, in this study, the reporting odds ratios (ROR) and proportional odds ratios (POR) were not used to link the events with the vaccines, but for the events with positive IC025, the ROR and POR with 95% credibility Interval were also mentioned. The event was not considered to be linked to the vaccine if its IC025 value was negative and the ROR or PRR was more than 1. The IC025 values were calculated separately for the different age groups and genders. Descriptive statistics were reported in the form of frequency and percentage. Statistical Package for Social Science version 17 (SPSS Inc., Chicago, IL, USA) was used for analysis. Institutional Ethics Committee exempted this project from the ethics review as this study is based on secondary data analysis which involves no direct contact with any human subject.
Results
This study is based on adverse events reported in the VigiBase database from December 15, 2020 to January 24, 2021. In this period, 103,954 adverse events were reported from 30,532 subjects who were administered the COVID-19 vaccine. Out of 103,954, 19,529 AEs were related to clinical events and investigations related to the neurological system. Total 15,638 events were reported from the BNT162b2 vaccine, 2,751 from AZD1222 vaccine, 1,075 from mRNA-1273 vaccine, eight from Vero vaccine, two from Covaxin, and for 55 AEs vaccine name was not mentioned. Neurological AEs reported from the abovementioned vaccines are summarized in Supplementary Tables 1-6.
Table 1. Disproportionality analysis of various neurological adverse events associated with COVID-19 vaccines.
OR - odd ratios; POR - proportional odd ratios
| TermText | Stratification (Full database/ Age/Gender) | Population | OR | IC025 | POR |
| Ageusia | Age group | 18 - 44 years | 6.3 (5.0-7.9) | 2.223 | 6.2(5.0-7.8) |
| Ageusia | Age group | Age group 45 - 64 years | 4.1(3.1-5.3) | 1.567 | 4.0(3.1-5.3) |
| Ageusia | Age group | Age Group unknown | 4.9(2.9-8.3) | 1.245 | 4.9(2.9-8.2) |
| Ageusia | Gender | Gender Male | 5.8(4.3-7.9) | 1.968 | 5.8 (4.3-7.8) |
| Ageusia | Gender | Gender Female | 4.0(3.3-4.8) | 1.668 | 3.9(3.3-4.8) |
| Ageusia | Full database | All subjects | 4.4(3.7-5.1) | 1.864 | 4.4(3.7-5.1) |
| Allodynia | Age group | Age group 18 - 44 years | 14.1(6.2-31.9) | 1.404 | 14.1(6.2-31.9) |
| Allodynia | Gender | Gender Female | 8.6(3.6-20.8) | 0.808 | 8.6(3.6-20.8) |
| Allodynia | Full database | All subjects | 11.2(5.3-23.6) | 1.466 | 11.2(5.3-23.6) |
| Anesthesia | Age group | Age group 45 - 64 years | 80.2(38.1-168.8) | 2.621 | 80.2(38.1-168.5) |
| Anesthesia | Gender | Gender Female | 34.6(17.7-68.0) | 2.520 | 34.6(17.7-68.0) |
| Anesthesia | Full database | All subjects | 32.1(17.0-60.5) | 2.640 | 32.1(17.0-60.4) |
| Anosmia | Age group | Age group 18 - 44 years | 10.3(7.9-13.3) | 2.808 | 10.2(7.9-13.3) |
| Anosmia | Age group | Age group 45 - 64 years | 5.9(4.3-8.1) | 1.976 | 5.9(4.3-8.1) |
| Anosmia | Age group | Age group 65 - 74 years | 11.3(4.2-30.3) | 0.658 | 11.3(4.2-30.0) |
| Anosmia | Age group | Age Group unknown | 12.2(7.7-19.9) | 2.508 | 12.1(7.7-18.9) |
| Anosmia | Gender | Gender Male | 12.8(9.3-17.6) | 2.959 | 12.7(9.3-17.5) |
| Anosmia | Gender | Gender Female | 6.3(5.1-7.9) | 2.271 | 6.3(5.1-7.8) |
| Anosmia | Full database | All subjects | 7.7(6.5-9.3) | 2.630 | 7.7(6.5-9.2) |
| Aura | Age group | Age group 18 - 44 years | 5.0(2.2-11.2) | 0.548 | 5.0(2.2-11.2) |
| Aura | Gender | Gender Female | 3.7(1.6-8.2) | 0.224 | 3.7(1.6-8.2) |
| Aura | Gender | Gender Male | 11.2(3.6-34.8) | 0.133 | 11.2(3.6-34.7) |
| Aura | Full database | All subjects | 4.9(2.6-9.5) | 0.935 | 4.9(2.6-9.5) |
| Balance disorder | Age group | Age group ≥ 75 years | 2.2(1.4-3.4) | 0.422 | 2.2(1.4-3.4) |
| Balance disorder | Gender | Gender Male | 1.7(1.1-2.4) | 0.128 | 1.7(1.1-2.4) |
| Burning sensation | Age group | Age group 18 - 44 years | 1.5(1.2-1.8) | 0.186 | 1.5 (1.2-1.8) |
| Burning sensation | Age group | Age group 45 - 64 years | 1.6(1.2-2.1) | 0.283 | 1.6(1.2-2.1) |
| Burning sensation | Gender | Gender Female | 1.4(1.1-1.6) | 0.185 | 1.4(1.1-1.6) |
| Burning sensation | Full database | All subjects | 1.5(1.3-1.8) | 0.356 | 1.5(1.3-1.8 ) |
| Cervicobrachial syndrome | Gender | Gender Female | 7.0(2.9-17.0) | 0.645 | 7.0(2.9-17.0) |
| Cervicobrachial syndrome | Full database | All subjects | 7.4(3.3-16.6) | 0.929 | 7.4(3.3-16.6) |
| Cluster headache | Age group | Age group 18 - 44 years | 15.2(9.2-25.1) | 2.566 | 15.1(9.2-25.0) |
| Cluster headache | Age group | Age group 45 - 64 years | 18.7(10.5-33.2) | 2.493 | 18.6(10.5-33.1) |
| Cluster headache | Gender | Gender Female | 24.0(16.4-35.0) | 3.468 | 24.0(16.4-35.0) |
| Cluster headache | Full database | All subjects | 19.5(13.6-27.9) | 3.333 | 19.5(13.6-27.8) |
| Dizziness | Age group | Age group 0 - 27 days | 15.3(5.4-43.6) | 0.761 | 13.6(5.4-34.4) |
| Dizziness | Age group | Age group 28 days to 23 months | 81.3(46.6-141.8) | 3.530 | 73.3(44.4-121.2) |
| Dizziness | Age group | Age group 2 - 11 years | 4.7(2.3-9.7) | 0.723 | 4.5(2.3-8.7) |
| Dizziness | Age group | Age group 18 - 44 years | 2.6(2.5-2.7) | 1.206 | 2.4(2.3-2.5) |
| Dizziness | Age group | Age group 45 - 64 years | 2.2(2.1-2.4) | 0.973 | 2.1(2.0-2.2) |
| Dizziness | Age group | Age group 65 - 74 years | 2.2(1.7-2.8) | 0.679 | 2.1(1.7-2.6) |
| Dizziness | Age group | Age group ≥ 75 years | 1.4(1.2-1.6) | 0.191 | 1.4(1.2-1.6) |
| Dizziness | Age group | Age Group unknown | 3.1(2.7-3.6) | 1.334 | 3.0(2.6-3.4) |
| Dizziness | Gender | Gender Male | 2.2(2.0-2.5) | 0.971 | 2.2(2.0-2.4) |
| Dizziness | Gender | Gender Female | 2.7(2.6-2.8) | 1.279 | 2.5(2.4-2.6) |
| Dizziness | Gender | Gender not known | 4.4(3.4-5.7) | 1.630 | 4.2(3.3-5.3) |
| Dizziness | Full database | All subjects | 2.8(2.7-2.9) | 1.356 | 2.7(2.6-2.7) |
| Dizziness postural | Age group | Age group 18 - 44 years | 21.1(16.7-26.6) | 3.790 | 21.0(16.7-26.4) |
| Dizziness postural | Age group | Age group 45 - 64 years | 13.7(10.2-18.5) | 3.095 | 13.7(10.2-18.5) |
| Dizziness postural | Age group | Age group 65 - 74 years | 16.4(6.8-39.6) | 1.239 | 16.3(6.8-39.1) |
| Dizziness postural | Age group | Age group ≥ 75 years | 6.8(3.2-14.4) | 1.030 | 6.8(3.2-14.3) |
| Dizziness postural | Age group | Age Group unknown | 13.8(6.9-27.7) | 1.802 | 13.7(6.9-27.5) |
| Dizziness postural | Gender | Gender Male | 8.5(5.3-13.5) | 2.065 | 8.4(5.3-13.4) |
| Dizziness postural | Gender | Gender Female | 17.4(14.5-20.9) | 3.711 | 17.3(14.5-20.8) |
| Dizziness postural | Gender | Gender not known | 48.6(19.9-118.5) | 1.654 | 48.3(19.9-117.2) |
| Dizziness postural | Full database | All Subjects | 15.5(13.1-18.3) | 3.605 | 15.4(13.1-18.2) |
| Dysgeusia | Age group | Age group 18 - 44 years | 3.7(3.3-4.3) | 1.665 | 3.7(3.2-4.2) |
| Dysgeusia | Age group | Age group 45 - 64 years | 3.7(3.2-4.3) | 1.642 | 3.7(3.2-4.2) |
| Dysgeusia | Age group | Age group 65 - 74 years | 3.1(1.7-5.8) | 0.458 | 3.1(1.7-5.7) |
| Dysgeusia | Age group | Age Group unknown | 3.1(2.2-4.5) | 0.998 | 3.1(2.1-4.5) |
| Dysgeusia | Gender | Gender Male | 2.6(2.0-3.4) | 0.950 | 2.6(2.0-3.4) |
| Dysgeusia | Gender | Gender Female | 3.6(3.3-4.0) | 1.683 | 3.6(3.2-4.0) |
| Dysgeusia | Gender | Gender not known | 7.6(4.9-11.9) | 1.982 | 7.5(4.8-11.5) |
| Dysgeusia | Full database | All Subjects | 3.7(3.4-4.1) | 1.733 | 3.7(3.4-4.0) |
| Dysstasia | Age group | Age group 18 - 44 years | 2.5(1.6-4.0) | 0.557 | 2.5(1.6-4.0) |
| Exertional headache | Gender | Gender Female | 57.8(20.6-162.3) | 1.228 | 57.8(20.6-162.2) |
| Exertional headache | Full database | All Subjects | 50.7(18.4-139.6) | 1.208 | 50.7(18.4-139.6) |
| Facial paralysis | Age group | Age group 18 - 44 years | 5.7(4.4-7.3) | 2.057 | 5.7(4.4-7.2) |
| Facial paralysis | Age group | Age group 45 - 64 years | 6.8(5.1-9.1) | 2.218 | 6.8(5.1-9.0) |
| Facial paralysis | Age group | Age group ≥ 75 years | 11.7(6.8-20.3) | 2.161 | 11.6(6.7-20.1) |
| Facial paralysis | Gender | Gender Male | 12.8(9.7-16.9) | 3.069 | 12.7(9.6-16.7) |
| Facial paralysis | Gender | Gender Female | 6.1(5.0-7.5) | 2.258 | 6.1(5.0-7.5) |
| Facial paralysis | Age group | Age Group unknown | 18.3(11.9-28.1) | 3.008 | 18.1(11.8-27.8) |
| Facial paralysis | Full database | All Subjects | 7.6(6.4-8.9) | 2.631 | 7.6(6.4-8.9) |
| Facial paresis | Age group | Age group 18 - 44 years | 5.2(3.1-8.8) | 1.311 | 5.2(3.1-8.8) |
| Facial paresis | Age group | Age group 45 - 64 years | 5.1(2.5-10.2) | 0.861 | 5.1(2.5-10.2) |
| Facial paresis | Age group | Age group ≥ 75 years | 10.4(3.3-32.4 ) | 0.093 | 10.4(3.3-32.3) |
| Facial paresis | Gender | Gender Male | 7.9(3.5-17.6) | 0.984 | 7.9(3.5-17.6) |
| Facial paresis | Gender | Gender Female | 4.7(3.0-7.4) | 1.407 | 4.7(3.0-7.4) |
| Facial paresis | Full database | All Subjects | 5.6(3.8-8.2) | 1.750 | 5.6(3.8-8.2) |
| Facial spasm | Age group | Age group 18 - 44 years | 7.2(3.4-15.2) | 1.065 | 7.2(3.4-15.2) |
| Facial spasm | Gender | Gender Female | 6.2(3.1-12.4) | 1.068 | 6.2(3.1-12.4) |
| Facial spasm | Full database | All Subjects | 6.1(3.2-11.8) | 1.173 | 6.1(3.2-11.8) |
| Febrile convulsion | Age group | Age group 18 - 44 years | 7.2(2.7-19.5) | 0.343 | 7.2(2.7-19.5) |
| Head discomfort | Age group | Age group 18 - 44 years | 2.2(1.5-3.2) | 0.544 | 2.2(1.5-3.2) |
| Head discomfort | Age group | Age group 45 - 64 years | 2.7(1.9-3.8) | 0.853 | 2.7(1.9-3.7) |
| Head discomfort | Gender | Gender Female | 2.1(1.6-2.7) | 0.643 | 2.1(1.6-2.7) |
| Head discomfort | Gender | Gender Male | 2.7(1.5-4.7) | 0.393 | 2.7(1.5-4.7) |
| Head discomfort | Full database | All Subjects | 2.4(1.9-3.0) | 0.865 | 2.4(1.9-3.0) |
| Headache | Age group | Age group 0 - 27 days | 43.9(18.9-101.7) | 2.151 | 35.0(17.9-68.6) |
| Headache | Age group | Age group 28 days to 23 months | 207.9(143.8-300.4) | 5.244 | 147.7(113.4-192.4) |
| Headache | Age group | Age group 2 - 11 years | 13.2(8.9-19.6) | 2.560 | 9.4(7.1-12.3) |
| Headache | Age group | Age group 12 - 17 years | 3.6(1.7-8.0) | 0.291 | 3.1(1.7-5.7) |
| Headache | Age group | Age group 18 - 44 years | 9.0(8.7-9.3) | 2.650 | 6.6(6.4-6.8) |
| Headache | Age group | Age group 45 - 64 years | 8.8(8.4-9.1) | 2.645 | 6.6(6.4-6.8) |
| Headache | Age group | Age group 65 - 74 years | 6.9(5.7-8.3) | 2.261 | 5.8(5.0-6.7) |
| Headache | Age group | Age group ≥ 75 years | 4.6(4.0-5.3) | 1.882 | 4.3(3.8-4.8) |
| Headache | Age group | Age Group unknown | 8.5(7.7-9.4) | 2.660 | 7.0(6.4-7.5) |
| Headache | Gender | Gender Male | 9.9(9.3-10.4) | 2.890 | 7.9(7.5-8.2) |
| Headache | Gender | Gender Female | 8.9(8.6-9.1) | 2.680 | 6.6(6.5-6.8) |
| Headache | Gender | Gender not known | 18.0(15.5-20.9) | 3.505 | 13.4(12.0-14.9) |
| Headache | Full database | All Subjects | 10.0(9.7-10.2) | 2.871 | 7.5(7.4-7.7) |
| Hemiparaesthesia | Age group | Age group 18 - 44 years | 17.1(6.2-46.8) | 0.853 | 17.1(6.2-46.8) |
| Hemiparaesthesia | Gender | Gender Female | 18.3(7.5-44.7) | 1.287 | 18.3(7.5-44.7) |
| Hemiparaesthesia | Full database | All Subjects | 21.1(9.4-47.5) | 1.660 | 21.1(9.4-47.5) |
| Hemiparesis | Age group | Age group ≥ 75 years | 4.9(2.7-8.9) | 1.081 | 4.9(2.7-8.8) |
| Hyperaesthesia | Age group | Age group 18 - 44 years | 2.8(1.9-4.2) | 0.797 | 2.8(1.9-4.2) |
| Hyperaesthesia | Gender | Gender Female | 2.7(1.9-3.8) | 0.829 | 2.7(1.9-3.8) |
| Hyperaesthesia | Full database | All Subjects | 2.7(1.9-3.7) | 0.890 | 2.7(1.9-3.7) |
| Hypersomnia | Age group | Age group 45 - 64 years | 3.0(2.0-4.3) | 0.897 | 3.0(2.0-4.3) |
| Hypersomnia | Gender | Gender Female | 1.7(1.3-2.3) | 0.283 | 1.7(1.3-2.3) |
| Hypersomnia | Full database | All Subjects | 1.6(1.2-2.2) | 0.260 | 1.6(1.2-2.2) |
| Hypoaesthesia | Age group | Age group 18 - 44 years | 2.7(2.4-2.9) | 1.233 | 2.6(2.4-2.9) |
| Hypoaesthesia | Age group | Age group 45 - 64 years | 2.8(2.5-3.1) | 1.258 | 2.7(2.4-3.1) |
| Hypoaesthesia | Age group | Age group 65 - 74 years | 2.7(1.6-4.7) | 0.459 | 2.7(1.6-4.60 |
| Hypoaesthesia | Age group | Age Group unknown | 2.3(1.6-3.3) | 0.601 | 2.3(1.6-3.2) |
| Hypoaesthesia | Gender | Gender Male | 2.5(2.0-3.1) | 0.985 | 2.5(2.0-3.0) |
| Hypoaesthesia | Gender | Gender Female | 3.0(2.8-3.3) | 1.459 | 3.0(2.8-3.2) |
| Hypoaesthesia | Gender | Gender not known | 6.5(4.0-10.6) | 1.704 | 6.4(4.0-10.3) |
| Hypoaesthesia | Full database | All Subjects | 3.3(3.1-3.5) | 1.586 | 3.2(3.0-3.5) |
| Hypogeusia | Age group | Age group 18 - 44 years | 4.7(1.9-11.4) | 0.278 | 4.7(1.9-11.4) |
| Hypogeusia | Gender | Gender Male | 6.8(2.5-18.1) | 0.305 | 6.8(2.5-18.1) |
| Hypogeusia | Full database | All Subjects | 3.0(1.5-6.0) | 0.252 | 3.0(1.5-6.0) |
| Hyporesponsive to stimuli | Gender | Gender Female | 4.7(2.0-11.4) | 0.285 | 4.7(2.0-11.4) |
| Hyposmia | Age group | Age group 18 - 44 years | 6.0(2.2-16.0) | 0.190 | 6.0(2.2-16.0) |
| Hyposmia | Age group | Age group 45 - 64 years | 8.1(3.6-18.0) | 0.996 | 8.0(3.6-18.0) |
| Hyposmia | Gender | Gender Male | 9.9(3.2-30.7) | 0.067 | 9.8(3.2-30.6) |
| Hyposmia | Gender | Gender Female | 5.7(2.7-12.1) | 0.856 | 5.7(2.7-12.1) |
| Hyposmia | Full database | All Subjects | 6.6(3.5-12.3) | 1.342 | 6.6(3.5-12.3) |
| Hypotonia | Age group | Age group ≥ 75 years | 5.3(2.4-11.8) | 0.605 | 5.3(2.4-11.7) |
| Ischaemic stroke | Age group | Age group ≥ 75 years | 3.6(2.0-6.6) | 0.726 | 3.6(2.0-6.6) |
| Lethargy | Gender | Not known | 17.0(11.2-25.7) | 2.976 | 16.5(11.0-24.8) |
| Lethargy | Age group | Age group 18 - 44 years | 8.0(7.0-9.1) | 2.734 | 7.9(6.9-8.9) |
| Lethargy | Age group | Age group unknown | 9.0(6.6-12.2) | 2.545 | 8.9(6.6-12.0) |
| Lethargy | Full database | All Subjects | 5.9(5.4-6.5) | 2.390 | 5.8(5.3-6.4) |
| Lethargy | Gender | Gender Female | 5.7(5.1-6.4) | 2.317 | 5.6(5.1-6.3) |
| Lethargy | Age group | Age group 45 - 64 years | 5.8(4.9-6.8) | 2.223 | 5.7(4.8-6.8) |
| Lethargy | Gender | Gender Male | 5.9(4.9-7.2) | 2.219 | 5.9(4.8-7.1) |
| Lethargy | Age group | Age group ≥ 75 years | 6.6(4.8-9.1) | 2.096 | 6.5(4.7-8.9) |
| Loss of consciousness | Age group | Age group ≥ 75 years | 1.8(1.2-2.7) | 0.113 | 1.7(1.2-2.6) |
| Migraine | Age group | Age group 2 - 11 years | 32.6(10.3-102.9) | 0.507 | 31.8(10.4-97.3) |
| Migraine | Age group | Age group 18 - 44 years | 4.3(3.8-4.8) | 1.887 | 4.2(3.8-4.7) |
| Migraine | Age group | Age group 45 - 64 years | 4.1(3.5-4.8) | 1.748 | 4.0(3.4-4.8) |
| Migraine | Age group | Age group 65 - 74 years | 5.0(2.1-12.2.) | 0.349 | 5.0(2.1-12.0) |
| Migraine | Age group | Age group ≥ 75 years | 4.7(2.1-10.6) | 0.500 | 4.7(2.1-10.6) |
| Migraine | Age group | Age Group unknown | 3.5(2.5-5.0) | 1.203 | 3.5(2.5-4.9) |
| Migraine | Gender | Gender Male | 7.5(5.8-9.6) | 2.420 | 7.4(5.8-9.5) |
| Migraine | Gender | Gender Female | 4.0(3.7-4.4) | 1.845 | 4.0(3.6-4.4) |
| Migraine | Gender | Gender not known | 8.2(5.1-13.3) | 1.976 | 8.1(5.0-12.9) |
| Migraine | Full database | All Subjects | 5.2(4.8-5.7) | 2.223 | 5.1(4.7-5.6) |
| Migraine with aura | Age group | Age group 18 - 44 years | 7.3(4.6-11.7) | 1.872 | 7.3(4.6-11.6) |
| Migraine with aura | Age group | Age group 45 - 64 years | 6.7(3.2-14.1) | 1.007 | 6.7(3.2-14.1) |
| Migraine with aura | Gender | Gender Female | 6.7(4.5-10.1) | 1.945 | 6.7(4.5-10.1) |
| Migraine with aura | Full database | All Subjects | 8.4(5.7-12.3) | 2.279 | 8.4(5.7-12.3) |
| Monoparesis | Gender | Gender Female | 3.6(1.6-8.1) | 0.209 | 3.6(1.6-8.1) |
| Neuralgia | Age group | Age group 18 - 44 years | 2.9(2.1-4.1) | 0.962 | 2.9(2.1-4.1) |
| Neuralgia | Age group | Age group 45 - 64 years | 1.9(1.2-2.9) | 0.203 | 1.9(1.2-2.9) |
| Neuralgia | Gender | Gender Male | 2.3(1.2-4.4) | 0.008 | 2.3(1.2-4.4) |
| Neuralgia | Gender | Gender Female | 2.1(1.6-2.7) | 0.592 | 2.1(1.6-2.7) |
| Neuralgia | Full database | All Subjects | 2.3(1.8-3.0) | 0.799 | 2.3(1.8-3.0) |
| Paraesthesia | Age group | Age group 28 days to 23 months | 70.1(22.1-222.2) | 0.634 | 68.6(22.2-212.3) |
| Paraesthesia | Age group | Age group 18 - 44 years | 3.6(3.3-3.9) | 1.676 | 3.5(3.2-3.7) |
| Paraesthesia | Age group | Age group 45 - 64 years | 3.9(3.5-4.2) | 1.756 | 3.7(3.4-4.1) |
| Paraesthesia | Age group | Age group 65 - 74 years | 2.4(1.4-4.0) | 0.317 | 2.4(1.4-4.0) |
| Paraesthesia | Age group | Age group ≥ 75 years | 1.7(1.1-2.6) | 0.049 | 1.7(1.1-2.6) |
| Paraesthesia | Age group | Age group unknown | 3.0(2.3-3.9) | 1.138 | 3.0(2.3-3.8) |
| Paraesthesia | Gender | Gender Male | 3.2(2.7-3.7) | 1.380 | 3.1(2.6-3.6) |
| Paraesthesia | Gender | Gender Female | 4.3(4.0-4.5) | 1.949 | 4.1(3.9-4.4) |
| Paraesthesia | Gender | Gender not known | 3.8(2.4-6.1) | 1.065 | 3.8(2.4-6.0) |
| Paraesthesia | Full database | All Subjects | 4.4(4.2-4.7) | 2.021 | 4.3(4.1-4.6) |
| Paresis | Age group | Age Group unknown | 14.2(4.6-44.3) | 0.248 | 14.2(4.6-44.2) |
| Parosmia | Age group | Age group 18 - 44 years | 2.8(1.7-4.7) | 0.574 | 2.8(1.7-4.7) |
| Parosmia | Age group | Age group 45 - 64 years | 2.4(1.4-4.1) | 0.350 | 2.4(1.4-4.1) |
| Parosmia | Gender | Gender Female | 2.5(1.7-3.7) | 0.702 | 2.5(1.7-3.7) |
| Parosmia | Full database | All Subjects | 2.5(1.8-3.6) | 0.763 | 2.5(1.8-3.6) |
| Petit mal epilepsy | Age group | Age group ≥ 75 years | 12.8(4.1-39.9) | 0.195 | 12.7(4.1-39.8) |
| Poor quality sleep | Age group | Age group 18 - 44 years | 2.4(1.5-3.7) | 0.462 | 2.4(1.5-3.7) |
| Poor quality sleep | Gender | Gender Female | 1.5(1.1-2.2) | 0.019 | 1.5(1.1-2.2) |
| Poor quality sleep | Full database | All Subjects | 1.6(1.1-2.2) | 0.133 | 1.6(1.1-2.2) |
| Presyncope | Age group | Age group 18 - 44 years | 9.1(7.8-10.7) | 2.869 | 9.0(7.7-10.5) |
| Presyncope | Age group | Age group 45 - 64 years | 8.3(6.7-10.4) | 2.645 | 8.3(6.7-10.3) |
| Presyncope | Age group | Age group 65 - 74 years | 4.8(1.8-12.9) | 0.017 | 4.8(1.8-12.8) |
| Presyncope | Age group | Age group ≥ 75 years | 2.9(1.6-5.3) | 0.450 | 2.9(1.6-5.3) |
| Presyncope | Age group | Age group unknown | 14.6(9.6-22.2) | 2.805 | 14.4(9.5-21.9) |
| Presyncope | Gender | Gender Male | 9.8(7.6-12.7) | 2.788 | 9.8(7.6-12.6) |
| Presyncope | Gender | Gender Female | 7.3(6.4-8.3) | 2.620 | 7.2(6.3-8.3) |
| Presyncope | Gender | Gender not known | 17.2(7.7-38.5) | 1.551 | 17.1(7.7-38.0) |
| Presyncope | Full database | All Subjects | 8.4(7.4-9.4) | 2.846 | 8.3(7.4-9.3) |
| Seizure | Age group | Age group ≥ 75 years | 1.9(1.2-3.0) | 0.162 | 1.9(1.2-3.0) |
| Seizure like phenomena | Full database | All Subjects | 3.3(1.6-6.9) | 0.247 | 3.3(1.6-6.9) |
| Sensory disturbance | Age group | Age group 45 - 64 years | 2.7(1.8-4.1) | 0.708 | 2.7(1.8-4.1) |
| Sensory disturbance | Gender | Gender Female | 1.7(1.2-2.4) | 0.247 | 1.7(1.2-2.4) |
| Sensory disturbance | Full database | All Subjects | 1.9(1.4-2.5) | 0.433 | 1.9(1.4-2.5) |
| Sensory loss | Age group | Age group 18 - 44 years | 3.5(2.2-5.5) | 0.952 | 3.5(2.2-5.5) |
| Sensory loss | Gender | Gender Female | 2.8(1.8-4.4) | 0.683 | 2.8(1.8-4.4) |
| Sensory loss | Full database | All Subjects | 2.6(1.7-3.9) | 0.617 | 2.6(1.7-3.9) |
| Sinus headache | Age group | Age group 18 - 44 years | 10.9(7.7-15.5) | 2.673 | 10.9(7.7-15.5) |
| Sinus headache | Age group | Age group 45 - 64 years | 6.8(4.4-10.6) | 1.863 | 6.8(4.4-10.6) |
| Sinus headache | Gender | Gender Male | 7.7(3.5-17.3) | 0.969 | 7.7(3.5-17.3) |
| Sinus headache | Gender | Gender Female | 8.1(6.2-10.7) | 2.491 | 8.1(6.2-10.7) |
| Sinus headache | Full database | All Subjects | 9.3(7.1-12.0) | 2.708 | 9.3(7.2-12.0) |
| Syncope | Age group | Age group 18 - 44 years | 1.8(1.5-2.1) | 0.579 | 1.8(1.5-2.1) |
| Syncope | Age group | Age group 45 - 64 years | 1.6(1.3-2.0) | 0.345 | 1.6(1.3-2.0) |
| Syncope | Age group | Age group 65 - 74 years | 2.6(1.4-4.7) | 0.289 | 2.6(1.4-4.6) |
| Syncope | Age group | Age Group unknown | 2.6(1.7-4.0) | 0.627 | 2.6(1.7-3.9) |
| Syncope | Gender | Gender Male | 1.5(1.2-2.0) | 0.171 | 1.5(1.2-2.0) |
| Syncope | Gender | Gender Female | 1.7(1.5-1.9) | 0.526 | 1.6(1.5-1.9) |
| Syncope | Full database | All Subjects | 1.7(1.5-1.9) | 0.573 | 1.7(1.5-1.9) |
| Taste disorder | Age group | Age group 18 - 44 years | 3.7(2.7-5.2) | 1.303 | 3.7(2.7-5.2) |
| Taste disorder | Age group | Age group 45 - 64 years | 3.5(2.4-5.0) | 1.162 | 3.5(2.4-5.0) |
| Taste disorder | Age group | Age Group unknown | 3.9(1.6-9.3) | 0.087 | 3.9(1.6-9.3) |
| Taste disorder | Gender | Gender Male | 3.3(1.9-5.8) | 0.667 | 3.3(1.9-5.8) |
| Taste disorder | Gender | Gender Female | 3.6(2.8-4.6) | 1.419 | 3.6(2.8-4.6) |
| Taste disorder | Full database | All Subjects | 3.8(3.0-4.7) | 1.531 | 3.8(3.0-4.7) |
| Tension headache | Age group | Age group 18 - 44 years | 18.6(14.2-24.3) | 3.535 | 18.5(14.2-24.2) |
| Tension headache | Age group | Age group 45 - 64 years | 13.0(8.6-19.6) | 2.692 | 12.9(8.6-19.6) |
| Tension headache | Age group | Age group ≥ 75 years | 23.3(9.6-56.6) | 1.405 | 23.2(9.6-56.4) |
| Tension headache | Age group | Age Group Unknown | 26.2(13.6-50.5) | 2.392 | 26.1(13.5-50.2) |
| Tension headache | Gender | Gender Male | 18.7(10.6-33.0) | 2.510 | 18.6(10.6-32.9) |
| Tension headache | Gender | Gender Female | 18.7(15.0-23.4) | 3.705 | 18.7(15.0-23.3) |
| Tension headache | Gender | Gender not known | 32.9(12.2-88.7) | 1.113 | 32.8(12.2-87.9) |
| Tension headache | Full database | All Subjects | 21.0(17.1-25.6) | 3.912 | 20.9(17.1-25.5) |
| Transient global amnesia | Age group | Age group 45 - 64 years | 12.7(4.7-34.3) | 0.717 | 12.7(4.7-34.3) |
| Transient global amnesia | Gender | Gender Female | 8.0(3.0-21.5) | 0.425 | 8.0(3.0-21.5) |
| Transient global amnesia | Full database | All Subjects | 5.9(2.2-15.8) | 0.193 | 5.9(2.2-15.8) |
| Transient ischaemic attack | Age group | Age group ≥ 75 years | 2.2(1.2-3.9) | 0.130 | 2.2(1.2-3.8) |
| Tremor | Age group | Age group 18 - 44 years | 1.7(1.5-1.9) | 0.538 | 1.6(1.5-1.8) |
| Tremor | Age group | Age group 45 - 64 years | 1.6(1.4-1.9) | 0.447 | 1.6(1.4-1.9) |
| Tremor | Age group | Age group ≥ 75 years | 1.5(1.1-2.0) | 0.097 | 1.5(1.1-2.0) |
| Tremor | Gender | Gender Female | 1.7(1.6-1.9) | 0.656 | 1.7(1.6-1.9) |
| Tremor | Full database | All Subjects | 1.7(1.6-1.9) | 0.660 | 1.7(1.6-1.9) |
| Tunnel vision | Age group | Age group 18 - 44 years | 8.8(5.1-15.3) | 1.856 | 8.8(5.1-15.3) |
| Tunnel vision | Gender | Gender Male | 13.6(5.6-32.7) | 1.129 | 13.6(5.6-32.7) |
| Tunnel vision | Gender | Gender Female | 9.0(5.1-15.8) | 1.818 | 9.0(5.1-5.8) |
| Tunnel vision | Full database | All Subjects | 9.9(6.1-15.9) | 2.197 | 9.9(6.1-15.9) |
| Unresponsive to stimuli | Age group | Age group 65 - 74 years | 20.1(10.7-37.6) | 2.353 | 19.8(10.7-36.8) |
| Unresponsive to stimuli | Age group | Age group ≥ 75 years | 14.1(10.0-19.9) | 2.993 | 13.9(9.9-19.6) |
| Unresponsive to stimuli | Gender | Gender Male | 4.4(3.1-6.3) | 1.498 | 4.4(3.1-6.3) |
| Unresponsive to stimuli | Gender | Gender Female | 2.2(1.6-3.0) | 0.634 | 2.2(1.6-3.0) |
| Unresponsive to stimuli | Full database | All Subjects | 2.6(2.1-3.3) | 1.011 | 2.6(2.1-3.3) |
As per the disproportionality analysis based on IC025 value, ageusia, allodynia, anesthesia, anosmia, aura, balance disorders, burning sensation, cervicobrachial syndrome, cluster headache, dizziness, postural dizziness, dysgeusia, exertional headache, facial paralysis, facial paresis, facial spasm, febrile convulsion, head discomfort, headache, hemiparaesthesia, hemiparesis, hyperaesthesis, hypersomnia, hypoaesthesia, hypogeusia, hyperresponsive to stimuli, hyposomnia, ischemic stroke, lethargy, loss of consciousness, migraine, migraine with aura, monoparesis, neuralgia, paraesthesia, paresis, parosmia, petit mal epilepsy, poor sleep quality, presyncope, seizure, sensory disturbance, sensory loss, sinus headache, syncope, taste disorder, tension headache, transient global amnesia, transient ischemic attack, tremor, tunnel vision, and unresponsive to stimuli are the AEs, which can be considered to be associated with the administration of the vaccine (Table 1).
Discussion
In this study, we inspected the VigiBase, the global pharmacovigilance database for the neurological adverse events reported for the COVID-19 vaccine. There was a total of 15,638 adverse events reported from BNT162b2 vaccine, 2,751 from AZD1222 vaccine, 1,075 from mRNA-1273 vaccine, eight from Vero vaccine, two from Covaxin, and for 55 AEs vaccine name was not mentioned.
When the disproportionality analysis was done based on the IC025 value, it was found that ageusia, allodynia, anaesthesia, anosmia, aura, balance disorders, burning sensation, cervicobrachial syndrome, cluster headache, dizziness, postural dizziness, dysgeusia, exertional headache, facial paralysis, facial paresis, facial spasm, febrile convulsion, head discomfort, headache, hemiparaesthesia, hemiparesis, hyperaesthesis, hypersomnia, hypoaesthesia, hypogeusia, hyperresponsive to stimuli, hyposomnia, ischemic stroke, lethargy, loss of consciousness, migraine, migraine with aura, monoparesis, neuralgia, paraesthesia, paresis, parosmia, petit mal epilepsy, poor sleep quality, presyncope, seizure, sensory disturbance, sensory loss, sinus headache, syncope, taste disorder, tension headache, transient global amnesia, transient ischemic attack, tremor, tunnel vision, and unresponsive to stimuli are the AEs those could be considered to have an association with the vaccine administration.
Frequently observed adverse events following vaccinations were headache, dizziness, paresthesia, hypoesthesia, lethargy, and migraine. Even though the total number of adverse events were high among individuals receiving BNT162b2 mRNA vaccine yet higher number of events in BNT162b2 mRNA vaccine can be explained as this is the first vaccine to receive emergency use authorization from USFDA, large number doses administration during the analysis period and a shorter interval between the two doses [36].
Polack et al. observed that frequently observed systemic adverse events following BNT162b2 mRNA vaccine second dose administration were fatigue (59%), headache (52%) in the younger population as compared to 51% and 39% among the older population, respectively [16]. In our analysis, headache accounted for 45.46% of the total adverse events with the BNT162b2 vaccine.
The fact sheet for healthcare providers administering BNT162b2 vaccine as published by FDA reported incidence of headache as 55.1% in participants of 16 years of age and older after the first dose and (75.5%) in adolescents of 12 through 15 years of age. In patients of age group 18-55 years reported that the prevalence of headache was 41.9% after dose 1 and 51.7% after dose 2 and 25.2% dose 1 and 39.0 % after dose 2 in 56 years of age and older vaccine recipients [37].
Similar adverse events were reported in the mRNA-1273 vaccine group. In clinical studies, adverse events were not presented as neurological per se, however, this analysis primarily focused on neurological manifestations. Headache was observed in 32.7 % of the total patients after the first vaccination and 58.6% after second vaccination and in both the instances the probability of headache was more in the ≥18 to <65 years group (first vaccination [35.3%] and second vaccination [62.8%]) as compared to the ≥65 years group recipients (first vaccination [24.5%] and second vaccination [46.2%]), respectively [38,39]. Similar results were published by the UK Department of Health and Social Care and the Medicines & Healthcare products Regulatory Agency for the AZD1222 vaccine where reporting AEs related to the nervous system disorders they showed headache as a very common category (Frequencies of occurrence: ≥1/10) which was reported by 52.6% of the vaccine recipients and as followed by dizziness, which was categorized as uncommon (frequencies of occurrence ≥1/1,000 to <1/100) [40]. Bell’s palsy was reported by four participants administered the BNT162b2 and by three participants in the mRNA-1273 vaccine group [37,39]. However, due to insufficient evidence and information, the causal relationship with the vaccines could not be established. The AEs reported with these COVID-19 vaccines may not be a true representation because neurological AEs like headaches are a common occurrence with vaccinations. A study by Cocores et al. conducted on Vaccine Adverse Events Reporting System (VAERS) reported that headache was the fifth most commonly reported adverse event post-vaccination after administration of any vaccine [41].
The disproportionality analysis of this study shows that the reactogenicity of the vaccine among individuals between 18 and 65 years was higher than the individuals above 65 years. This finding was supported by a few previously published clinical studies where a similar type of difference was observed with mRNA-1273, BNT162b2, and AZD1222 vaccines [16,38,42].
Early analysis of all adverse events following vaccination as reported in the COVID-19 vaccine safety update Advisory Committee on Immunization Practices (ACIP) by March 1, 2021, shows that more than 90% were non-serious in nature and headache was the commonest reported AE in both the mRNA vaccines with 20% with BNT162b2 and 23.4 % with the mRNA-1273 vaccine [43]. In a later report as of June 23, 2021, the ACIP in their early safety data of Pfizer-BioNTech vaccination in persons aged 12-15 years and 16-25 years old reported headache as one of the commonest reported adverse events [44]. Similar reports of headache (22.4%) were also reported by the Morbidity and Mortality Weekly Report by CDC, as per the data collected in VAERS in the early phase of vaccination [45]. This difference may be because of the inclusion of local and systemic adverse events, whereas in this study we have included only systemic neurological manifestations. The serious adverse events reported in the VigiBase need to be scrutinized for their association with vaccine administration. In the earlier clinical trials, the majority of serious adverse events were either unrelated to the vaccine or were coincidental due to age-related risk factors.
Immune reactogenicity to vaccines refers to a group of reactions that are observed immediately after vaccination and are a physical presentation of the inflammatory response to the vaccination. Reactogenicity is determined by either host factors such as age, gender, preexisting immunity or vaccine characteristics, or both [46]. Systemic manifestations of reactogenicity are either due to the vaccine or its adjuvants or both. Presentation of these manifestations varies from fever, headache, dizziness, to seizures and life-threatening anaphylaxis. The systemic pyrogens and other immune mediators cross-talk with the nervous system through the vagus nerve, at the blood-brain barrier, and circumventricular organs. All adjuvant systems induce transient systemic innate responses, which include an increase in the levels of IL-6 and C-reactive protein (CRP), usually peaking at 24 hours after vaccination and subsides to the baseline values within one to three days [47].
The vaccine adjunct can also have a role in reactogenicity. The mRNA vaccines enveloped with lipid nanoparticle (LNP) based delivery system mimics as virus and prevent them from enzymatic digestion along with enhancing immunogenicity without integrating with the genome. However, mRNA itself causes immunogenicity with activation of pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α), Interleukin (IL)-6 and IL-12 and other innate reactivity manifests as systemic reactions including neurological adverse events. LNP used as an adjuvant precipitates reactogenicity through B-cell amplification and antigen-specific CD4+ and CD8+ T cell responses [48].
Strength of study
This study is based on VigiBase, a large global database of spontaneous reports of AEs used by Uppsala Monitoring Centre, Sweden to generate AEs related signals and used in various published studies to link adverse events with drug use. To avoid any kind of false-positive association, the most conservative method of disproportionality analysis, i.e. IC025 values, was used.
Limitations of the study
The data in this study were taken from VigiBase which includes information from varied sources. The probability that the suspected adverse effect is caused by the drug cannot be ascertained for all the cases. The information provided does not represent the opinion of the UMC or the WHO. The data in the study are from a limited duration and to draw conclusive evidence, larger studies with long-term data need to be analyzed.
Conclusions
Future prospects and conclusion
With numerous molecules being experimented with for the therapy of COVID-19, vaccines have given a ray of hope to curb this pandemic. Almost 15 approved vaccines around the world were being administered in different countries after receiving emergency approval from their respective licensing authorities. These vaccines, in view of an emergency need across the globe, were developed in a short period of time and tried in the clinical trials for a brief period as compared to usual vaccine development. The adverse events with these vaccines are known on the basis of the clinical trials done but long-term and rare adverse events were unclear and are now being revealed with the wide administration drives of vaccination across the globe. All the adverse events associated with any drug or therapy are ultimately reported to the international database called VigiBase hence it is better to analyze their data to find out the common adverse events associated with any therapy across the world. The neurological adverse events associated with these vaccines were not frequent and a headache was one of the common adverse events reported. There were some reported rare serious neurological adverse events but their causal association with the vaccines was to be established. As there can be many predisposing conditions in the patients and interaction with them could also lead to a particular adverse event, hence it was too early to associate a particular adverse event with the vaccines. These reported adverse events can serve as a preliminary signal for potential ADRs associated with these vaccines but based on these results one must not conclude the safety of the above-analyzed vaccines. Moreover, these reported events are adverse events and do not have adverse drug reactions hence definitive causality of the reported events could not be assessed. Therefore long-term robust follow-up studies or cohort studies must be conducted with close monitoring of the adverse events reported establishing the safety of these vaccines.
The current study tries to summarize various neurological manifestations reported in patients who received the vaccines by analyzing the VigiBase, which can help find the common neurological AEs, which can help the prescribers in better management of the public vaccination program and also help in building public awareness and alleviating existing public perceptions.
Appendices
Table 2. Supplementary Table 1: Neurological adverse drug events suspected to be caused by Pfizer vaccine use in COVID-19.
| Broad heading | Specific adverse event | Non-serious n (%) (n=11,625) | Serious n (%) (n=3,991) | Total n (%) (n=15,616) |
| Nervous System Disorder(N=15616) | Acoustic neuritis | 1(0.01) | 0(0.00) | 1(0.01) |
| Acute disseminated encephalomyelitis | 0(0.00) | 2(0.05) | 1(0.01) | |
| Ageusia | 106(0.91) | 32(0.80) | 138(0.88) | |
| Akathisia | 1(0.01) | 0(0.00) | 1(0.01) | |
| Allodynia | 3(0.03) | 1(0.03) | 4(0.03) | |
| Altered state of consciousness | 1(0.01) | 5(0.13) | 6(0.04) | |
| Amnesia | 5(0.04) | 3(0.08) | 8(0.05) | |
| Anaesthesia | 8(0.07) | 0(0.00) | 8(0.05) | |
| Anosmia | 89(0.77) | 25(0.63) | 114(0.73) | |
| Anticholinergic syndrome | 0(0.00) | 1(0.03) | 1(0.01) | |
| Aphasia | 6(0.05) | 8(0.20) | 14(0.09) | |
| Areflexia | 0(0.00) | 4(0.10) | 4(0.03) | |
| Ataxia | 2(0.02) | 2(0.05) | 4(0.03) | |
| Aura | 6(0.05) | 2(0.05) | 890.05) | |
| Balance disorder | 42(0.36) | 25(0.63) | 67(0.43) | |
| Band sensation | 3(0.03) | 0(0.00) | 3(0.02) | |
| Basal ganglia haemorrhage | 0(0.00) | 1(0.03) | 1(0.01) | |
| Basilar artery occlusion | 0(0.00) | 1(0.03) | 1(0.01) | |
| Bradykinesia | 2(0.02) | 0(0.00) | 1(0.01) | |
| Brain oedema | 1(0.01) | 0(0.00) | 1(0.01) | |
| Brain stem infarction | 0(0.00) | 1(0.03) | 1(0.01) | |
| Burning sensation | 104(0.89) | 30(0.75) | 134(0.86) | |
| Burning sensation mucosal | 1(0.01) | 0(0.00) | 1(0.01) | |
| Carpal tunnel syndrome | 1(0.01) | 0(0.00) | 1(0.01) | |
| Central nervous system lesion | 0(0.00) | 4(0.10) | 4(0.03) | |
| Cerebellar haemorrhage | 0(0.00) | 1(0.03) | 1(0.01) | |
| Cerebellar infarction | 0(0.00) | 1(0.03) | 1(0.01) | |
| Cerebellar stroke | 0(0.00) | 1(0.03) | 1(0.01) | |
| Cerebral artery occlusion | 0(0.00) | 1(0.03) | 1(0.01) | |
| Cerebral haemorrhage | 0(0.00) | 6(0.15) | 6(0.04) | |
| Cerebral infarction | 0(0.00) | 4(0.10) | 4(0.03) | |
| Cerebral venous sinus thrombosis | 0(0.00) | 1(0.03) | 1(0.01) | |
| Cerebrovascular accident | 3(0.03) | 22(0.55) | 25(0.16) | |
| Cervicobrachial syndrome | 4(0.03) | 1(0.03) | 5(0.03) | |
| Cervicogenic headache | 1(0.01) | 0(0.00) | 1(0.01) | |
| Cholinergic syndrome | 1(0.01) | 0(0.00) | 1(0.01) | |
| Clonic convulsion | 1(0.01) | 0(0.00) | 1(0.01) | |
| Clumsiness | 1(0.01) | 1(0.03) | 1(0.01) | |
| Cluster headache | 12(0.10) | 6(0.15) | 18(0.12) | |
| Cognitive disorder | 1(0.01) | 4(0.10) | 5(0.03) | |
| Cold-stimulus headache | 1(0.01) | 0(0.00) | 1(0.01) | |
| Coma | 0(0.00) | 2(0.05) | 1(0.01) | |
| Complex regional pain syndrome | 1(0.01) | 2(0.05) | 3(0.02) | |
| Consciousness fluctuating | 0(0.00) | 2(0.05) | 1(0.01) | |
| Coordination abnormal | 6(0.05) | 5(0.13) | 11(0.07) | |
| Cranial nerve disorder | 2(0.02) | 2(0.05) | 4(0.03) | |
| Dementia | 1(0.01) | 2(0.05) | 3(0.02) | |
| Dementia of the Alzheimer's type, with delirium | 0(0.00) | 1(0.03) | 1(0.01) | |
| Demyelination | 0(0.00) | 1(0.03) | 1(0.01) | |
| Depressed level of consciousness | 10(0.09) | 11(0.28) | 21(0.13) | |
| Disturbance in attention | 52(0.45) | 18(0.45) | 70(0.45) | |
| Dizziness | 1954(16.81) | 595(14.95) | 2549 | |
| Dizziness exertional | 1(0.01) | 1(0.03) | 1(0.01) | |
| Dizziness postural | 50(0.43) | 29(0.73) | 79(0.51) | |
| Dreamy state | 0(0.00) | 1(0.03) | 1(0.01) | |
| Drooling | 0(0.00) | 1(0.03) | 1(0.01) | |
| Dysaesthesia | 10(0.09) | 1(0.03) | 11(0.07) | |
| Dysarthria | 11(0.09) | 14(0.35) | 25(0.16) | |
| Dysgeusia | 348(2.99) | 41(1.03) | 389(2.49) | |
| Dyskinesia | 11(0.09) | 4(0.10) | 15(0.10) | |
| Dysstasia | 19(0.16) | 6(0.15) | 25(0.16) | |
| Dystonia | 0(0.00) | 2(0.05) | 1(0.01) | |
| Encephalitis post immunisation | 0(0.00) | 1(0.03) | 1(0.01) | |
| Encephalopathy | 0(0.00) | 1(0.03) | 1(0.01) | |
| Epilepsy | 2(0.02) | 9(0.23) | 11(0.07) | |
| Essential tremor | 1(0.01) | 0(0.00) | 1(0.01) | |
| Exertional headache | 2(0.02) | 1(0.03) | 3(0.02) | |
| Extrapyramidal disorder | 0(0.00) | 2(0.05) | 1(0.01) | |
| Facial nerve disorder | 4(0.03) | 0(0.00) | 4(0.03) | |
| Facial neuralgia | 2(0.02) | 0(0.00) | 1(0.01) | |
| Facial paralysis | 799).68) | 51(1.28) | 130(0.83) | |
| Facial paresis | 9(0.08) | 13(0.33) | 22(0.14) | |
| Facial spasm | 5(0.04) | 2(0.05) | 7(0.04) | |
| Febrile convulsion | 1(0.01) | 3(0.08) | 4(0.03) | |
| Fine motor skill dysfunction | 1(0.01) | 1(0.03) | 1(0.01) | |
| Formication | 7(0.06) | 2(0.05) | 9(0.06) | |
| Generalised tonic-clonic seizure | 2(0.02) | 7(0.18) | 9(0.06) | |
| Guillain-Barre syndrome | 1(0.01) | 3(0.08) | 4(0.03) | |
| Haemorrhage intracranial | 0(0.00) | 5(0.13) | 5(0.03) | |
| Head discomfort | 40(0.34) | 12(0.30) | 52(0.33) | |
| Head titubation | 1(0.01) | 0(0.00) | 1(0.01) | |
| Headache | 5285(45.46) | 1582(39.64) | 6867(43.97) | |
| Hemianaesthesia | 3(0.03) | 0(0.00) | 3(0.02) | |
| Hemidysaesthesia | 1(0.01) | 0(0.00) | 1(0.01) | |
| Hemihyperaesthesia | 1(0.01) | 0(0.00) | 1(0.01) | |
| Hemiparaesthesia | 3(0.03) | 2(0.05) | 6(0.04) | |
| Hemiparesis | 1(0.01) | 16(0.40) | 17(0.11) | |
| Horner's syndrome | 0(0.00) | 1(0.03) | 1(0.01) | |
| Hyperaesthesia | 16(0.14) | 5(0.13) | 21(0.13) | |
| Hypersomnia | 32(0.28) | 6(0.15) | 389(0.24) | |
| Hypertonia | 2(0.02) | 0(0.00) | 1(0.01) | |
| Hypoaesthesia | 572(4.92) | 144(3.61) | 716(4.59) | |
| Hypogeusia | 7(0.06) | 0(0.00) | 7(0.04) | |
| Hypokinesia | 3(0.03) | 3(0.08) | 6(0.04) | |
| Hyporeflexia | 1(0.01) | 3(0.08) | 4(0.03) | |
| Hyporesponsive to stimuli | 2(0.02) | 3(0.08) | 5(0.03) | |
| Hyposmia | 7(0.06) | 2(0.05) | 9(0.06) | |
| Hypotonia | 10(0.09) | 3(0.08) | 13(0.08) | |
| Incoherent | 1(0.01) | 0(0.00) | 1(0.01) | |
| Intracranial aneurysm | 0(0.00) | 1(0.03) | 1(0.01) | |
| Ischaemic stroke | 0(0.00) | 16(0.40) | 16(0.10) | |
| IVth nerve paralysis | 0(0.00) | 1(0.03) | 1(0.01) | |
| Lacunar infarction | 0(0.00) | 2(0.05) | 1(0.01) | |
| Lacunar stroke | 0(0.00) | 2(0.05) | 1(0.01) | |
| Language disorder | 2(0.02) | 3(0.08) | 5(0.03) | |
| Lethargy | 212(1.82) | 139(3.48) | 351(2.25) | |
| Locked-in syndrome | 0(0.00) | 1(0.03) | 1(0.01) | |
| Loss of consciousness | 46(0.40) | 40(1.00) | 86(0.55) | |
| Loss of proprioception | 0(0.00) | 1(0.03) | 1(0.01) | |
| Memory impairment | 14(0.12) | 7(0.18) | 21(0.13) | |
| Mental impairment | 7(0.06) | 1(0.03) | 8(0.05) | |
| Migraine | 255(2.19) | 121(3.03) | 376(2.41) | |
| Migraine with aura | 17(0.15) | 5(0.13) | 22(0.14) | |
| Migraine without aura | 1(0.01) | 0(0.00) | 1(0.01) | |
| Mononeuropathy | 0(0.00) | 1(0.03) | 1(0.01) | |
| Monoparesis | 2(0.02) | 3(0.08) | 5(0.03) | |
| Monoplegia | 3(0.03) | 1(0.03) | 4(0.03) | |
| Motor dysfunction | 2(0.02) | 0(0.00) | 1(0.01) | |
| Movement disorder | 13(0.11) | 2(0.05) | 15(0.10) | |
| Multiple sclerosis | 0(0.00) | 1(0.03) | 1(0.01) | |
| Multiple sclerosis relapse | 1(0.01) | 1(0.03) | 1(0.01) | |
| Muscle contractions involuntary | 7(0.06) | 2(0.05) | 9(0.06) | |
| Muscle spasticity | 0(0.00) | 1(0.03) | 1(0.01) | |
| Muscle tone disorder | 0(0.00) | 1(0.03) | 1(0.01) | |
| Myasthenia gravis | 0(0.00) | 2(0.05) | 1(0.01) | |
| Myelitis transverse | 0(0.00) | 1(0.03) | 1(0.01) | |
| Myoclonus | 2(0.02) | 2(0.05) | 4(0.03) | |
| Narcolepsy | 0(0.00) | 1(0.03) | 1(0.01) | |
| Nerve compression | 3(0.03) | 0(0.00) | 3(0.02) | |
| Nervous system disorder | 5(0.04) | 0(0.00) | 5(0.03) | |
| Neuralgia | 37(0.32) | 12(0.30) | 49(0.31) | |
| Neuralgic amyotrophy | 0(0.00) | 3(0.08) | 3(0.02) | |
| Neuritis | 2(0.02) | 0(0.00) | 1(0.01) | |
| Neurological symptom | 3(0.03) | 3(0.08) | 7(0.04) | |
| Neuropathy peripheral | 12(0.10) | 5(0.13) | 17(0.11) | |
| New daily persistent headache | 1(0.01) | 0(0.00) | 1(0.01) | |
| Noninfective encephalitis | 0(0.00) | 1(0.03) | 1(0.01) | |
| Nystagmus | 2(0.02) | 3(0.08) | 5(0.03) | |
| Occipital neuralgia | 1(0.01) | 0(0.00) | 1(0.01) | |
| Optic neuritis | 1(0.01) | 1(0.03) | 1(0.01) | |
| Orthostatic intolerance | 1(0.01) | 0(0.00) | 1(0.01) | |
| Paraesthesia | 901(7.75) | 201(5.04) | 1102(7.06) | |
| Paralysis | 8(0.07) | 10(0.25) | 18(0.12) | |
| Paraparesis | 0(0.00) | 1(0.03) | 1(0.01) | |
| Paresis | 5(0.04) | 2(0.05) | 7(0.04) | |
| Paresis cranial nerve | 1(0.01) | 0(0.00) | 1(0.01) | |
| Parkinsonian gait | 1(0.01) | 0(0.00) | 1(0.01) | |
| Parkinsonism | 0(0.00) | 1(0.03) | 1(0.01) | |
| Parosmia | 24(0.21) | 4(0.10) | 28(0.18) | |
| Partial seizures | 1(0.01) | 0(0.00) | 1(0.01) | |
| Peripheral sensory neuropathy | 0(0.00) | 3(0.08) | 3(0.02) | |
| Peroneal nerve palsy | 0(0.00) | 1(0.03) | 1(0.01) | |
| Persistent postural-perceptual dizziness | 1(0.01) | 0(0.00) | 1(0.01) | |
| Petit mal epilepsy | 3(0.03) | 1(0.03) | 4(0.03) | |
| Polyneuropathy | 1(0.01) | 0(0.00) | 1(0.01) | |
| Poor quality sleep | 22(0.19) | 4(0.10) | 26(0.17) | |
| Posterior reversible encephalopathy syndrome | 0(0.00) | 1(0.03) | 1(0.01) | |
| Postictal state | 2(0.02) | 0(0.00) | 1(0.01) | |
| Presyncope | 177(1.52) | 79(1.98) | 256(1.64) | |
| Primary headache associated with sexual activity | 1(0.01) | 0(0.00) | 1(0.01) | |
| Psychogenic seizure | 1(0.01) | 1(0.03) | 1(0.01) | |
| Psychomotor hyperactivity | 3(0.03) | 1(0.03) | 5(0.03) | |
| Radial nerve palsy | 0(0.00) | 1(0.03) | 1(0.01) | |
| Radiculitis brachial | 0(0.00) | 1(0.03) | 1(0.01) | |
| Radiculopathy | 2(0.02) | 1(0.03) | 3(0.02) | |
| Reduced facial expression | 0(0.00) | 1(0.03) | 1(0.01) | |
| Restless legs syndrome | 7(0.06) | 3(0.08) | 10(0.06) | |
| Retinal migraine | 0(0.00) | 1(0.03) | 1(0.01) | |
| Reversible cerebral vasoconstriction syndrome | 0(0.00) | 1(0.03) | 1(0.01) | |
| Sciatica | 7(0.06) | 2(0.05) | 9(0.06) | |
| Sedation | 1(0.01) | 1(0.03) | 1(0.01) | |
| Seizure | 16(0.14) | 40(1.00) | 56(0.36) | |
| Seizure like phenomena | 2(0.02) | 3(0.08) | 5(0.03) | |
| Sensory disturbance | 30(0.26) | 7(0.18) | 37(0.24) | |
| Sensory loss | 10(0.09) | 9(0.23) | 19(0.12) | |
| Serotonin syndrome | 1(0.01) | 0(0.00) | 1(0.01) | |
| Sinus headache | 33(0.28) | 14(0.35) | 47(0.30) | |
| Slow response to stimuli | 2(0.02) | 0(0.00) | 1(0.01) | |
| Slow speech | 3(0.03) | 0(0.00) | 3(0.02) | |
| Small fibre neuropathy | 0(0.00) | 1(0.03) | 1(0.01) | |
| Somnolence | 167(1.44) | 49(1.23) | 216(1.38) | |
| Speech disorder | 17(0.15) | 18(0.45) | 35(0.22) | |
| Status epilepticus | 0(0.00) | 2(0.05) | 1(0.01) | |
| Stiff leg syndrome | 0(0.00) | 1(0.03) | 1(0.01) | |
| Stupor | 1(0.01) | 1(0.03) | 1(0.01) | |
| Subarachnoid haemorrhage | 2(0.02) | 1(0.03) | 3(0.02) | |
| Sudden onset of sleep | 1(0.01) | 0(0.00) | 1(0.01) | |
| Syncope | 140(1.20) | 99(2.48) | 239(1.53) | |
| Taste disorder | 50(0.43) | 11(0.28) | 61(0.39) | |
| Tension headache | 45(0.39) | 18(0.45) | 63(0.40) | |
| Thunderclap headache | 0(0.00) | 1(0.03) | 1(0.01) | |
| Tongue biting | 1(0.01) | 0(0.00) | 1(0.01) | |
| Tonic clonic movements | 2(0.02) | 0(0.00) | 1(0.01) | |
| Tonic convulsion | 1(0.01) | 1(0.03) | 1(0.01) | |
| Transient global amnesia | 0(0.00) | 3(0.08) | 3(0.02) | |
| Transient ischaemic attack | 3(0.03) | 9(0.23) | 12(0.08) | |
| Tremor | 257(2.21) | 128(3.21) | 385(2.47) | |
| Trigeminal neuralgia | 5(0.04) | 1(0.03) | 6(0.04) | |
| Trigeminal neuritis | 1(0.01) | 0(0.00) | 1(0.01) | |
| Tunnel vision | 10(0.09) | 3(0.08) | 13(0.08) | |
| Typical aura without headache | 1(0.01) | 0(0.00) | 1(0.01) | |
| Unresponsive to stimuli | 10(0.09) | 37(0.93) | 47(0.30) | |
| Vestibular migraine | 0(0.00) | 11(0.03) | 1(0.01) | |
| Visual field defect | 3(0.03) | 3(0.08) | 6(0.04) | |
| Writer's cramp | 0(0.00) | 1(0.03) | 1(0.01) | |
| Investigations (N=22) | Angiogram cerebral abnormal | 0(0.00) | 1(5.88) | 1(4.55) |
| Brain natriuretic peptide increased | 0(0.00) | 2(0.05) | 2(9.09) | |
| Carotid bruit | 0(0.00) | 1(5.88) | 1(4.55) | |
| Computerised tomogram head abnormal | 2(40.00) | 0(0.00) | 2(9.09) | |
| CSF protein increased | 0(0.00) | 2(11.76) | 2(9.09) | |
| Electroencephalogram abnormal | 0(0.00) | 1(5.88) | 1(4.55) | |
| Magnetic resonance imaging brain abnormal | 1(20.00) | 6(35.29) | 7(31.82) | |
| Magnetic resonance imaging spinal abnormal | 0(0.00) | 1(5.88) | 1(4.55) | |
| Neurological examination abnormal | 1(20.00) | 2(11.76) | 3(13.64) | |
| NIH stroke scale abnormal | 0(0.00) | 1(5.88) | 1(4.55) | |
| Sensory level abnormal | 1(20.00) | 0(0.00) | 1(4.55) |
Table 3. Supplementary Table 2: Neurological adverse drug events suspected to be caused by Astra Zeneca vaccine use in COVID-19.
| Broad heading | Specific adverse event | Non-serious n(%) (n=1,527) | Serious n(%) (n=1,224) | Total n(%) (n=2,751) |
| Nervous System Disorder(N=2751) | Ageusia | 5(0.33) | 5(0.41) | 10(0.36) |
| Allodynia | 2(0.13) | 1(0.08) | 3(0.11) | |
| Amnesia | 1(0.07) | 0(0.00) | 1(0.04) | |
| Anosmia | 1(0.07) | 4(0.330 | 5(0.18) | |
| Aphasia | 0(0.00) | 2(0.16) | 2(0.07) | |
| Balance disorder | 2(0.13) | 7(0.57) | 9(0.33) | |
| Brain stem stroke | 0(0.00) | 1(0.08) | 1(0.04) | |
| Burning sensation | 0(0.00) | 2(0.16) | 2(0.07) | |
| Cerebrovascular accident | 0(0.00) | 3(0.25) | 3(0.11) | |
| Cervicobrachial syndrome | 1(0.07) | 0(0.00) | 1(0.04) | |
| Clumsiness | 0(0.00) | 1(0.08) | 1(0.04) | |
| Cluster headache | 4(0.26) | 5(0.41) | 9(0.33) | |
| Cognitive disorder | 1(0.07) | 1(0.08) | 2(0.07) | |
| Coordination abnormal | 1(0.07) | 0(0.00) | 1(0.04) | |
| Disturbance in attention | 2(0.13) | 4(0.33) | 6(0.22) | |
| Dizziness | 180(11.79) | 154(12.58) | 334(12.14) | |
| Dizziness postural | 11(0.72) | 1290.98) | 23(0.84) | |
| Dysarthria | 0(0.00) | 1(0.08) | 1(0.04) | |
| Dysgeusia | 23(1.51) | 11(0.90) | 34(1.24) | |
| Dysstasia | 0(0.00) | 2(0.16) | 2(0.07) | |
| Epilepsy | 0(0.00) | 2(0.16) | 2(0.07) | |
| Facial paralysis | 2(0.13) | 1(0.08) | 3(0.11) |
Table 4. Supplementary Table 3: Neurological adverse drug events suspected to be caused by Moderna vaccine use in COVID-19.
| Broad heading | Specific adverse event | Non-serious n(%) (n=803) | Non-serious n(%) (n=269) | Total n(%) (n=1,072) |
| Nervous System Disorder(N=1072) | Ageusia | 4(0.50) | 0(0.00) | 4(0.37) |
| Akathisia | 1(0.12) | 0(0.00) | 1(0.09) | |
| Anosmia | 3(0.37) | 0(0.00) | 3(0.28) | |
| Anterograde amnesia | 0(0.00) | 1(0.37) | 11(0.09) | |
| Aphasia | 1(0.12) | 4(1.49) | 5(0.47) | |
| Aura | 1(0.12) | 0(0.00) | 1(0.09) | |
| Balance disorder | 6(0.75) | 1(0.37) | 7(0.65) | |
| Burning sensation | 6(0.75) | 4(1.49) | 10(0.93) | |
| Cerebral haemorrhage | 1(0.12) | 0(0.00) | 1(0.09) | |
| Cerebral ischaemia | 1(0.12) | 0(0.00) | 1(0.09) | |
| Cerebrovascular accident | 0(0.00) | 4(1.49) | 4(0.37) | |
| Cognitive disorder | 0(0.00) | 1(0.37) | 1(0.09) | |
| Consciousness fluctuating | 0(0.00) | 1(0.37) | 1(0.09) | |
| Dementia | 0(0.00) | 1(0.37) | 1(0.09) | |
| Depressed level of consciousness | 0(0.00) | 2(0.74) | 2(0.19) | |
| Disturbance in attention | 2(0.25) | 0(0.00) | 2(0.19) | |
| Dizziness/Dizziness postural | 179(22.29) | 39(14.50) | 218(20.34) | |
| Drooling | 0(0.00) | 1(0.37) | 1(0.09) | |
| Dysarthria | 4(0.50) | 7(2.60) | 11(1.03) | |
| Dysgeusia | 20(2.49) | 0(0.00) | 20(1.87) | |
| Dysstasia | 4(0.50) | 1(0.37) | 5(0.47) | |
| Dystonic tremor | 0(0.00) | 1(0.37) | 1(0.09) | |
| Encephalomalacia | 1(0.12) | 0(0.00) | 1(0.09) | |
| Facial paralysis | 4(0.50) | 9(3.35) | 13(1.21) | |
| Facial paresis | 0(0.00) | 2(0.74) | 2(0.19) | |
| Generalised tonic-clonic seizure | 0(0.00) | 1(0.37) | 1(0.09) | |
| Guillain-Barre syndrome | 0(0.00) | 1(0.37) | 1(0.09) | |
| Haemorrhagic stroke | 0(0.00) | 1(0.37) | 1(0.09) | |
| Head discomfort | 5(0.62) | 0(0.00) | 5(0.47) | |
| Headache | 299(37.34) | 37(13.75) | 336(31.34) | |
| Hemianopia | 0(0.00) | 1(0.37) | 1(0.09) | |
| Hemiparesis | 1(0.12) | 3(1.12) | 4(0.37) | |
| Hemiplegia | 0(0.00) | 1(0.37) | 1(0.09) | |
| Hyperaesthesia | 1(0.12) | 0(0.00) | 1(0.09) | |
| Hypersomnia | 7(0.87) | 0(0.00) | 7(0.65) | |
| Hypertonia | 0(0.00) | 1(0.37) | 1(0.09) | |
| Hypoaesthesia | 59(7.35) | 22(8.18) | 81(7.56) | |
| Hypokinesia | 0(0.00) | 1(0.37) | 1(0.09) | |
| Hypotonia | 0(0.00) | 2(0.74) | 2(0.19) | |
| Incoherent/Incoherent Speech disorder | 1(0.12) | 3(1.12) | 4(0.37) | |
| Intracranial aneurysm | 0(0.00) | 1(0.37) | 1(0.09) | |
| Ischaemic stroke | 0(0.00) | 1(0.37) | 1(0.09) | |
| Lacunar infarction | 1(0.12) | 00(0.00) | 1(0.09) | |
| Lethargy | 9(1.12) | 3(1.12) | 12(1.12) | |
| Loss of consciousness | 9(1.12) | 7(2.60) | 16(1.49) | |
| Memory impairment | 3(0.37) | 6(2.23) | 9(0.84) | |
| Migraine | 16(1.99) | 3(1.12) | 19(1.77) | |
| Monoplegia | 1(0.12) | 00(0.00) | 1(0.09) | |
| Motor dysfunction | 0(0.00) | 1(0.37) | 1(0.09) | |
| Muscle contractions involuntary | 1(0.12) | 0(0.00) | 1(0.09) | |
| Neuralgia | 1(0.12) | 1(0.37) | 2(0.19) | |
| Neurologic neglect syndrome | 0(0.00) | 1(0.37) | 1(0.09) | |
| Neurological symptom | 0(0.00) | 1(0.37) | 1(0.09) | |
| Opisthotonus | 0(0.00) | 1(0.37) | 1(0.09) | |
| Paraesthesia | 70(8.72) | 15(5.58) | 85(7.93) | |
| Poor quality sleep | 0(0.00) | 1(0.37) | 1(0.09) | |
| Posterior reversible encephalopathy syndrome | 0(0.00) | 1(0.37) | 11(0.09) | |
| Presyncope | 11(1.37) | 2(0.74) | 13(1.21) | |
| Reflexes abnormal | 0(0.00) | 1(0.37) | 1(0.09) | |
| Repetitive speech | 0(0.00) | 1(0.37) | 1(0.09) | |
| Sedation | 1(0.12) | 0(0.00) | 1(0.09) | |
| Seizure | 0(0.00) | 6(2.23) | 6(0.56) | |
| Seizure like phenomena | 0(0.00) | 1(0.37) | 1(0.09) | |
| Sensory disturbance | 3(0.37) | 2(0.74) | 5(0.47) | |
| Sinus headache | 1(0.12) | 0(0.00) | 1(0.09) | |
| Somnolence | 8(1.00) | 4(1.49) | 12(1.12) | |
| Speech disorder | 1(0.12) | 11(4.09) | 12(1.12) | |
| Syncope | 11(1.37) | 11(4.09) | 22(2.25) | |
| Taste disorder | 0(0.00) | 2(0.74) | 2(0.19) | |
| Thrombotic stroke | 0(0.00) | 1(0.37) | 1(0.09) | |
| Transient ischaemic attack | 0(0.00) | 1(0.37) | 1(0.09) | |
| Tremor | 38(4.73) | 11(0.37) | 49(4.57) | |
| Tunnel vision | 3(0.37) | 0(0.00) | 3(0.28) | |
| Unresponsive to stimuli | 3(0.37) | 19(7.06) | 22(2.05) | |
| Visual field defect | 1(0.12) | 0(0.00) | 1(0.09) | |
| Investigations(N=3) | Coma scale abnormal | 0(0.00) | 1(50.00) | 1(33.33) |
| Computerised tomogram head abnormal | 0(0.00) | 1(50.00) | 1(33.33) | |
| Magnetic resonance imaging brain abnormal | 1(0.12) | 0(0.00) | 1(33.33) |
Table 5. Supplementary Table 4: Neurological adverse drug events suspected to be caused by Vero vaccine use in COVID-19.
| Broad heading | Specific adverse event | Non-serious n(%) (n=4) | Serious n(%) (n=2) | Total n(%) (n=6) |
| Nervous System Disorder (N=6) | Cerebral venous sinus thrombosis | 0(0.00) | 1(50.0) | 1(16.77) |
| Dizziness | 4(100.0) | 0(0.00) | 4(66.67) | |
| Headache | 0(0.00) | 1(50.0) | 1(16.67) |
Table 6. Supplementary Table 5: Neurological adverse drug events suspected to be caused by Covaxin vaccine use in COVID-19.
| Broad heading | Specific adverse event | Non-serious n(%) (n=2) | Serious n(%) (n=0) | Total n(%) (n=2) |
| Nervous System Disorder(N=2) | Headache | 2(100.0) | 0(0.00) | 2(100.0) |
Table 7. Supplementary Table 6: Neurological adverse drug events suspected to be caused by unknown vaccine use in COVID-19.
| Broad heading | Specific adverse event | Non-serious n (%) (n=39) | Serious n (%) (n=16) | Total n(%) (n=55) |
| Nervous System Disorder(n=55) | Balance disorder | 0(0.00) | 1(6.25) | 1(1.82) |
| Cerebrovascular accident | 0(0.00) | 1(6.25) | 1(1.82) | |
| Dizziness | 5(12.82) | 2(12.5) | 7(12.73) | |
| Dysgeusia | 1(2.56) | 1(6.25) | 2(3.64) | |
| Dysstasia | 0(0.00) | 1(6.25) | 1(1.82) | |
| Headache | 22(56.41) | 4(25.0) | 26(47.27) | |
| Hypoaesthesia | 1(2.56) | 0(0.00) | 1(1.82) | |
| Lethargy | 1(2.56) | 1(6.25) | 2(3.64) | |
| Migraine | 1(2.56) | 1(6.25) | 2(3.64) | |
| Paraesthesia | 1(2.56) | 0(0.00) | 3(5.45) | |
| Presyncope | 1(2.56) | 1(6.25) | 2(3.64) | |
| Sinus headache | 1(2.56) | 0(0.00) | 1(1.82) | |
| Syncope | 1(2.56) | 1(6.25) | 2(3.64) | |
| Taste disorder | 1(2.56) | 0(0.00) | 1(1.82) | |
| Transient ischaemic attack | 0(0.00) | 1(6.25) | 1(1.82) | |
| Tremor | 1(2.56) | 1(6.25) | 2(3.64) |
The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.
The authors have declared that no competing interests exist.
Human Ethics
Consent was obtained or waived by all participants in this study
Animal Ethics
Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue.
References
- 1.WHO coronavirus disease (COVID-19) dashboard. [ Dec; 2021 ];https://covid19.who.int/ 2021
- 2.Household transmission of COVID-19: a cross-sectional study. Dutta S, Kaur RJ, Bhardwaj P, et al. Infect Drug Resist. 2020;13:4637–4642. doi: 10.2147/IDR.S285446. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Rapid assessment of price instability and paucity of medicines and protection for COVID-19 across Asia: findings and public health implications for the future. Godman B, Haque M, Islam S, et al. Front Public Health. 2020;8:585832. doi: 10.3389/fpubh.2020.585832. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Utilisation, availability and price changes of medicines and protection equipment for COVID-19 among selected regions in India: fndings and implications. Haque M, Kumar S, Charan J, et al. Front Pharmacol. 2020;11:582154. doi: 10.3389/fphar.2020.582154. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Use of complementary and alternative medicine (CAM) and home remedies by COVID-19 patients: a telephonic survey. Charan J, Bhardwaj P, Dutta S, et al. Indian J Clin Biochem. 2021;36:108–111. doi: 10.1007/s12291-020-00931-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database. Charan J, Dutta S, Kaur R, et al. Expert Opin Drug Saf. 2021;20:1125–1136. doi: 10.1080/14740338.2021.1946513. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Hydroxychloroquine as therapeutic option in COVID- 19: analysis of suspected cardiovascular adverse drug events reported in the VigiBase. Dutta S, Kaur R, Bhardwaj P, et al. Bangladesh J Med Sci. 2021;6:897–910. [Google Scholar]
- 8.Fat-soluble vitamins and the current global pandemic of COVID-19: evidence-based efficacy from literature review. Samad N, Dutta S, Sodunke TE, et al. J Inflamm Res. 2021;19:2091–2110. doi: 10.2147/JIR.S307333. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.The implications of zinc therapy in combating the COVID-19 global pandemic. Samad N, Sodunke TE, Abubakar AR, et al. J Inflamm Res. 2021;14:527–550. doi: 10.2147/JIR.S295377. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Favipiravir use in COVID-19: analysis of suspected adverse drug events reported in the WHO database. Kaur RJ, Charan J, Dutta S, et al. Infect Drug Resist. 2020;13:4427–4438. doi: 10.2147/IDR.S287934. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications. Charan J, Kaur RJ, Bhardwaj P, Haque M, Sharma P, Misra S, Godman B. Expert Rev Clin Pharmacol. 2021;14:95–103. doi: 10.1080/17512433.2021.1856655. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.A review on current repurposing drugs for the treatment of COVID-19: reality and challenges. Hossen MS, Barek MA, Jahan N, Safiqul Islam M. SN Compr Clin Med. 2020:1–13. doi: 10.1007/s42399-020-00485-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Regulatory Focus:COVID-19 vaccine tracker: Regulatory Affairs Professionals Society (RAPS) [ Mar; 2021 ];Craven J. https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker 2021
- 14.Adverse events reported from COVID-19 vaccine trials: a systematic review. Kaur RJ, Dutta S, Bhardwaj P, et al. Indian J Clin Biochem. 2021:1–13. doi: 10.1007/s12291-021-00968-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Lancet. 2021;397:671–681. doi: 10.1016/S0140-6736(21)00234-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. Vergnes JN. N Engl J Med. 2021;384:1577. doi: 10.1056/NEJMc2036242. [DOI] [PubMed] [Google Scholar]
- 17.COVID vaccine 'side effect' or functional neurological disorder? [ May; 2021 ];Hughes S. https://www.medscape.com/viewarticle/949294 2021
- 18.Helping the public understand adverse events associated with COVID-19 vaccinations: lessons learned from functional neurological disorder. Kim DD, Kung CS, Perez DL. JAMA Neurol. 2021;78:789–790. doi: 10.1001/jamaneurol.2021.1042. [DOI] [PubMed] [Google Scholar]
- 19.The potential neurological effect of the COVID-19 vaccines: a review. Lu L, Xiong W, Mu J, et al. Acta Neurol Scand. 2021;144:3–12. doi: 10.1111/ane.13417. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Uppsala Monitoring Centre: WHO Programme for International Drug Monitoring. [ May; 2021 ];https://www.who-umc.org/vigibase/vigibase/ VigiBase. 2020
- 21.Adverse events reported from the COVID-19 vaccines: a descriptive study based on the WHO database (VigiBase®) Dutta S, Kaur R, Bhardwaj P, et al. J Appl Pharm Sci. 2021;11:1–9. [Google Scholar]
- 22.Cardiovascular adverse events reported from COVID-19 vaccines: a study based on WHO database. Jeet Kaur R, Dutta S, Charan J, et al. Int J Gen Med. 2021;14:3909–3927. doi: 10.2147/IJGM.S324349. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Uppsala Monitoring Centre: WHO Programme for International Drug Monitoring. VigiBase FAQs. https://www.who-umc.org/vigibase/vigibase/know-more-about-vigibase/ 202020217
- 24.VigiBase: signalling harm and pointing to safer use. [ May; 2020 ];Uppsala Monitoring Centre. https://www.who-umc.org/vigibase/vigibase/vigibase-signalling-harm-and-pointing-to-safer-use/ 2020 10 [Google Scholar]
- 25.WHO collaborating centre for drug statistics methodology. [ May; 2021 ];https://www.whocc.no/ Methodology. 2020
- 26.The medical dictionary for regulatory activities (MedDRA) Brown EG, Wood L, Wood S. Drug Saf. 1999;20:109–117. doi: 10.2165/00002018-199920020-00002. [DOI] [PubMed] [Google Scholar]
- 27.ICH Harmonised Tripartite Guideline Maintenance Of The Ich Guideline On Clinical Safety Data Management :Data Elements For Transmission Of Individual Case Safety Reports E2B(R2) [cited. https://admin.ich.org/sites/default/files/inline-files/E2B_R2_Guideline.pdf 20219
- 28.International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Medical Dictionary for Regulatory Activities(MedDRA) https://www.meddra.org/how-to-use/support-documentation/english/welcome 2020202114
- 29.International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) [ May; 2020 ];https://www.meddra.org/how-to-use/basics/hierarchy MedDRA Hierarchy. 2020
- 30.Glossary of pharmacovigilance terms. [ May; 2020 ];Uppsala Monitoring Centre. https://www.who-umc.org/global-pharmacovigilance/publications/glossary/ Glossary of pharmacovigilance terms. 2020
- 31.A Bayesian neural network method for adverse drug reaction signal generation. Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RM. Eur J Clin Pharmacol. 1998;54:315–321. doi: 10.1007/s002280050466. [DOI] [PubMed] [Google Scholar]
- 32.Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M. Br J Clin Pharmacol. 2011;72:905–908. doi: 10.1111/j.1365-2125.2011.04037.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.A comparison of measures of disproportionality for signal detection on adverse drug reaction spontaneous reporting database of Guangdong province in China. Li C, Xia J, Deng J, Jiang J. Pharmacoepidemiol Drug Saf. 2008;17:593–600. doi: 10.1002/pds.1601. [DOI] [PubMed] [Google Scholar]
- 34.Novel data-mining methodologies for adverse drug event discovery and analysis. Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Clin Pharmacol Ther. 2012;91:1010–1021. doi: 10.1038/clpt.2012.50. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Quantitative signal detection using spontaneous ADR reporting. Bate A, Evans SJ. Pharmacoepidemiol Drug Saf. 2009;18:427–436. doi: 10.1002/pds.1742. [DOI] [PubMed] [Google Scholar]
- 36.COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna vaccines. Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. Eur Rev Med Pharmacol Sci. 2021;25:1663–1669. doi: 10.26355/eurrev_202102_24877. [DOI] [PubMed] [Google Scholar]
- 37.Food and Drug Administration. Fact Sheet for healthcare providers administering vaccine emergency use authorization (EUA) of The Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019. [ May; 2021 ];https://www.fda.gov/media/144413/download 2021
- 38.Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. Baden LR, El Sahly HM, Essink B, et al. N Engl J Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Food and Drug Administration. Fact sheet for healthcare providers administering vaccine (vaccination providers) emergency use authorization (EUA) of the Moderna Covid-19 vaccine to prevent coronavirus disease 2019. [ May; 2021 ];https://www.fda.gov/media/144637/download 2021
- 40.Medicines & Healthcare products Regulatory Agency. Information for UK recipients on COVID 19 vaccine AstraZeneca. [ Mar; 2021 ];https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca/information-for-uk-recipients-on-covid-19-vaccine-astrazeneca 2021
- 41.Post-vaccination headache reporting trends according to the vaccine adverse events reporting system (VAERS) (P1.147) Cocores A, Monteith T. https://n.neurology.org/content/86/16_Supplement/P1.147. Neurology. 2016;86:1–147. doi: 10.1111/head.14458. [DOI] [PubMed] [Google Scholar]
- 42.Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Ramasamy MN, Minassian AM, Ewer KJ, et al. Lancet. 2021;396:1979–1993. doi: 10.1016/S0140-6736(20)32466-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Centers for Disease Control and Prevention: COVID-19 vaccine safety update: Advisory Committee on Immunization Practices (ACIP) CDC COVID-19 Vaccine Task Force; March 1, 2021. [ May; 2021 ];Shimabukuro T. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-02/28-03-01/05-covid-Shimabukuro.pdf CDC COVID-19 Vaccine Task Force. 2021 1:2021–2025. [Google Scholar]
- 44.Centers for Disease Control and Prevention: COVID-19 vaccine safety update: Advisory Committee on Immunization Practices (ACIP) June 23, 2021. [ Dec; 2021 ];Shimabukuro T. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-06/03-COVID-Shimabukuro-508.pdf 2021 Vaccine Task Force;:2021–2027. [Google Scholar]
- 45.First month of COVID-19 vaccine safety monitoring — United States, December 14, 2020-January 13, 2021. Gee J, Marquez P, Su J, et al. https://www.cdc.gov/mmwr/volumes/70/wr/mm7008e3.htm. MMWR Morb Mortal Wkly Rep. 2021;70:283–288. doi: 10.15585/mmwr.mm7008e3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.The how's and what's of vaccine reactogenicity. Hervé C, Laupèze B, Del Giudice G, Didierlaurent AM, Da Silva FT. NPJ Vaccines. 2019;4:39. doi: 10.1038/s41541-019-0132-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Different adjuvants induce common innate pathways that are associated with enhanced adaptive responses against a model antigen in humans. Burny W, Callegaro A, Bechtold V, et al. Front Immunol. 2017;8:943. doi: 10.3389/fimmu.2017.00943. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Nanomaterial delivery systems for mRNA vaccines. Buschmann MD, Carrasco MJ, Alishetty S, Paige M, Alameh MG, Weissman D. Vaccines (Basel) 2021;9:65. doi: 10.3390/vaccines9010065. [DOI] [PMC free article] [PubMed] [Google Scholar]